Literature DB >> 17095199

Dopamine D2 receptor binding in drug-naïve patients with schizophrenia examined with raclopride-C11 and positron emission tomography.

Mirjam Talvik1, Anna-Lena Nordström, Yoshiro Okubo, Hans Olsson, Jacqueline Borg, Christer Halldin, Lars Farde.   

Abstract

The aim was to test the dopamine hypothesis of schizophrenia in a further analysis of D(2)-like dopamine binding using the radioligand [(11)C]raclopride and high resolution 3-dimensional (3D) PET. Eighteen drug-naive patients with schizophrenia and seventeen control subjects were examined. The D(2) binding potential (BP) in the putamen, the caudate and the thalamus was calculated using the simplified reference tissue model. The volume of regions of interest was controlled for by MRI. Symptoms were rated with the Positive and Negative Syndrome Scale for Schizophrenia (PANSS). No significant group differences were found for D(2) BP in the putamen or in the caudate and there was no significant hemispheric difference for any region. In the right thalamus the D(2) BP was significantly lower in patients as compared to control subjects, whereas a numerical difference did not reach statistical significance for the left thalamus. There was no significant correlation between D(2) BP and total PANSS score in any region. There was a highly significant age effect in the caudate and in the putamen, but not in the thalamus. In this relatively large PET study of exclusively drug-naive schizophrenic patients, a lower D(2) BP in the right thalamus was found in the patient group. This finding is in agreement with two previous studies in Sweden and in Japan using the high-affinity radioligand [(11)C]FLB 457 and provide further support for a role of dopamine in the thalamus related to the pathophysiology of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17095199     DOI: 10.1016/j.pscychresns.2006.05.009

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  23 in total

Review 1.  Is schizophrenia a dopamine supersensitivity psychotic reaction?

Authors:  Mary V Seeman; Philip Seeman
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-10-12       Impact factor: 5.067

2.  The relationship between excitement symptom severity and extrastriatal dopamine D2/3 receptor availability in patients with schizophrenia: a high-resolution PET study with [18F]fallypride.

Authors:  Yo-Han Joo; Jeong-Hee Kim; Young-Don Son; Hang-Keun Kim; Yeon-Jeong Shin; Sang-Yoon Lee; Jong-Hoon Kim
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-06-16       Impact factor: 5.270

3.  Dopamine D₂/₃ receptor availability in the striatum of antipsychotic-free older patients with schizophrenia-A [¹¹C]-raclopride PET study.

Authors:  Shinichiro Nakajima; Fernando Caravaggio; David C Mamo; Benoit H Mulsant; Jun Ku Chung; Eric Plitman; Yusuke Iwata; Philip Gerretsen; Hiroyuki Uchida; Takefumi Suzuki; Wanna Mar; Alan A Wilson; Sylvain Houle; Ariel Graff-Guerrero
Journal:  Schizophr Res       Date:  2015-03-08       Impact factor: 4.939

4.  Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia.

Authors:  Sarah A Eisenstein; Ryan Bogdan; Ling Chen; Stephen M Moerlein; Kevin J Black; Joel S Perlmutter; Tamara Hershey; Deanna M Barch
Journal:  J Psychiatr Res       Date:  2016-11-17       Impact factor: 4.791

5.  18F-fallypride binding potential in patients with schizophrenia compared to healthy controls.

Authors:  Douglas S Lehrer; Bradley T Christian; Cemil Kirbas; Meicheng Chiang; Shawn Sidhu; Holly Short; Binquan Wang; Bingzhi Shi; King-Wai Chu; Brian Merrill; Monte S Buchsbaum
Journal:  Schizophr Res       Date:  2010-07-23       Impact factor: 4.939

6.  Thinking outside a less intact box: thalamic dopamine D2 receptor densities are negatively related to psychometric creativity in healthy individuals.

Authors:  Orjan de Manzano; Simon Cervenka; Anke Karabanov; Lars Farde; Fredrik Ullén
Journal:  PLoS One       Date:  2010-05-17       Impact factor: 3.240

Review 7.  Pathway-Specific Dopamine Abnormalities in Schizophrenia.

Authors:  Jodi J Weinstein; Muhammad O Chohan; Mark Slifstein; Lawrence S Kegeles; Holly Moore; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2016-03-31       Impact factor: 13.382

8.  [11C]cyclopropyl-FLB 457: a PET radioligand for low densities of dopamine D2 receptors.

Authors:  Anu J Airaksinen; Sangram Nag; Sjoerd J Finnema; Jogeshwar Mukherjee; Sankha Chattopadhyay; Balázs Gulyás; Lars Farde; Christer Halldin
Journal:  Bioorg Med Chem       Date:  2008-05-20       Impact factor: 3.641

Review 9.  Dopamine hypothesis of schizophrenia: making sense of it all.

Authors:  Mitsuru Toda; Anissa Abi-Dargham
Journal:  Curr Psychiatry Rep       Date:  2007-08       Impact factor: 5.285

Review 10.  The dopamine hypothesis of schizophrenia: version III--the final common pathway.

Authors:  Oliver D Howes; Shitij Kapur
Journal:  Schizophr Bull       Date:  2009-03-26       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.